However, not all patients whose tumors are sensitive to HSP90 inhibitors respond positively to treatment, meaning that the use of HSP90 inhibition as a therapy in lung adenocarcinoma remains limited due to moderate drug efficacy, the emergence of drug resistance, and early tumor recurrence [38]. This evidence concerns the gene HSP90AB1 and neoplasm.